ASCO 2026: Highlights and analysis
ASCO 2026: Highlights and analysis
Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer
Short-term fasting linked to improved chemo response in advanced ovarian cancer
ASCO 2026: Latest in prostate cancer
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission
Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups
Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC
ASCO 2026: Latest updates in mRCC
Combination therapeutic strategies for aRCC patients with bone metastases
ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas
DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer